Bupivacaine extended release - Pacira Pharmaceuticals

Drug Profile

Bupivacaine extended release - Pacira Pharmaceuticals

Alternative Names: Bupivacaine extended-release - Pacira Pharmaceuticals; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SkyePharma Inc
  • Developer Pacira Pharmaceuticals
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Postoperative pain
  • Preregistration Anaesthesia
  • Phase III Dental pain
  • No development reported Musculoskeletal pain; Pain

Most Recent Events

  • 08 Nov 2017 FDA assigns PDUFA action date of 06/04/2018 for Bupivacaine extended release - Pacira Pharmaceuticals for Anaesthesia (via Nerve block)
  • 08 Nov 2017 Pacira Pharmaceuticals resubmits sNDA for Bupivacaine extended release - Pacira Pharmaceuticals for Anaesthesia (via Nerve block) in USA before November 2017
  • 08 Nov 2017 US FDA accepts sNDA for Bupivacaine extended release - Pacira Pharmaceuticals for Anaesthesia (via Nerve block)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top